ASCENDIS PHARMA A/S - ADR (ASND) Forecast, Price Target & Analyst Ratings

NASDAQ:ASND • US04351P1012

Current stock price

240.29 USD
-5.09 (-2.07%)
At close:
240.29 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for ASCENDIS PHARMA A/S - ADR (ASND).

Forecast Snapshot

Consensus Price Target

Price Target
$299.54
+ 24.66% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Apr 29, 2026
Period
Q1 / 2026
EPS Estimate
€0.30
Revenue Estimate
279.93M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
88.33%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$299.54
Upside
+ 24.66%
From current price of $240.29 to mean target of $299.54, Based on 24 analyst forecasts
Low
$257.55
Median
$296.82
High
$359.10

Price Target Revisions

1 Month
3.56%
3 Months
10.11%

Price Target Summary

24 Wall Street analysts provided a forecast for the next 12 months for ASND. The average price target is 299.54 USD. This implies a price increase of 24.66% is expected in the next year compared to the current price of 240.29.
The average price target has been revised upward by 10.11% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

ASND Current Analyst RatingASND Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

ASND Historical Analyst RatingsASND Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20

Analyst Ratings Consensus

ChartMill Buy Consensus
88.33%
ASND was analyzed by 24 analysts. The buy percentage consensus is at 88. So analysts seem to be very confident about ASND.
In the previous month the buy percentage consensus was at a similar level.
ASND was analyzed by 24 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-04-16B of A SecuritiesMaintains Buy -> Buy
2026-04-09WedbushReiterate Outperform -> Outperform
2026-03-03RBC CapitalMaintains Outperform -> Outperform
2026-02-12OppenheimerMaintains Outperform -> Outperform
2026-02-12WedbushMaintains Outperform -> Outperform
2026-01-30B of A SecuritiesMaintains Buy -> Buy
2026-01-28BarclaysInitiate Overweight
2026-01-20RBC CapitalMaintains Outperform -> Outperform
2026-01-20Wells FargoMaintains Overweight -> Overweight
2026-01-09Wells FargoMaintains Overweight -> Overweight
2026-01-07TD CowenReiterate Buy -> Buy
2025-12-11StifelMaintains Buy -> Buy
2025-11-18WedbushReiterate Outperform -> Outperform
2025-10-17Raymond JamesInitiate Strong Buy
2025-10-13Cantor FitzgeraldMaintains Overweight -> Overweight
2025-10-09JP MorganMaintains Overweight -> Overweight
2025-09-02B of A SecuritiesMaintains Buy -> Buy
2025-08-19JP MorganMaintains Overweight -> Overweight
2025-08-08Cantor FitzgeraldMaintains Overweight -> Overweight
2025-08-08UBSMaintains Buy -> Buy
2025-08-08RBC CapitalMaintains Outperform -> Outperform
2025-08-08StifelMaintains Buy -> Buy
2025-08-08WedbushMaintains Outperform -> Outperform
2025-08-08Wells FargoMaintains Overweight -> Overweight
2025-08-08CitigroupMaintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
Apr 29, 2026
Period
Q1 / 2026
EPS Estimate
€0.30
Revenue Estimate
279.93M
Revenue Q2Q
177.28%
EPS Q2Q
118.94%
Number of Analysts
17

Next Earnings Revisions

Revenue (1 Month)
-2.50%
Revenue (3 Months)
-0.17%
EPS (1 Month)
-19.77%
EPS (3 Months)
-19.40%

Next Earnings Summary

ASND is expected to report earnings on 4/29/2026. The consensus EPS estimate for the next earnings is 0.3 USD and the consensus revenue estimate is 279.93M USD.
The next earnings revenue estimate has been revised downward by 0.17% in the past 3 months.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
ASND revenue by date.ASND revenue by date.
266.718M
421.24%		363.641M
36.34%		720.132M
98.03%		1.414B
96.35%		2.049B
44.91%		2.567B
25.28%		3.035B
18.23%		3.399B
11.99%		3.512B
3.32%		3.79B
7.92%		3.98B
5.01%
EBITDA
YoY % growth
ASND ebitda by date.ASND ebitda by date.
-428.796M
21.16%		-261.049M
39.12%		-118.575M
54.58%		430.87M
463.37%		896.4M
108.04%		1.381B
54.06%		N/AN/AN/AN/AN/A
EBIT
YoY % growth
ASND ebit by date.ASND ebit by date.
-447.707M
20.31%		-278.763M
37.74%		-136.271M
51.12%		349.16M
356.22%		790.25M
126.33%		1.148B
45.27%		1.457B
26.92%		1.73B
18.74%		1.66B
-4.05%		1.852B
11.57%		1.971B
6.43%
Operating Margin
ASND operating margin by date.ASND operating margin by date.
-167.86%-76.66%-18.92%24.69%38.57%44.72%48.01%50.90%47.27%48.87%49.52%
EPS
YoY % growth
ASND eps by date.ASND eps by date.
-8.56
17.69%		-6.57
23.25%		-3.77
42.62%		4.45
217.92%		10.98
146.99%		14.96
36.23%		22.52
50.54%		26.10
15.89%		25.62
-1.81%		27.83
8.61%		29.38
5.57%

All data in EUR

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth		0.30
118.94%		0.76
218.56%		1.25
224.73%		2.11
484.15%		1.58
428.31%		1.85
143.30%		2.24
79.91%		1.36
-35.79%
Revenue
Q2Q % growth		279.93M
177.28%		329.95M
108.77%		374.61M
75.35%		422.5M
70.71%		425.03M
51.83%		458.69M
39.02%		502.04M
34.02%		549.68M
30.10%
EBITDA
Q2Q % growth		44.407M
148.19%		73.869M
267.51%		106.05M
344.30%		115.45M
318.42%		N/AN/AN/AN/A
EBIT
Q2Q % growth		31.066M
132.12%		63.273M
219.49%		97.666M
788.11%		128.99M
1,203.46%		122.4M
294.00%		142.8M
125.69%		173.4M
77.54%		205.02M
58.94%

All data in EUR

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

ASND Yearly Revenue VS EstimatesASND Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 1B 2B 3B
ASND Yearly EPS VS EstimatesASND Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 10 -10 20

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
81.39%
EPS Next 5 Year
54.92%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
52.11%
Revenue Next 5 Year
36.05%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
132.04%
EBIT Next 5 Year
N/A
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

ASCENDIS PHARMA A/S - ADR / ASND Forecast FAQ

What do analysts expect the price target to be for ASCENDIS PHARMA A/S - ADR (ASND)?

24 analysts have analysed ASND and the average price target is 299.54 USD. This implies a price increase of 24.66% is expected in the next year compared to the current price of 240.29.

Can you provide the upcoming earnings date for ASCENDIS PHARMA A/S - ADR?

ASCENDIS PHARMA A/S - ADR (ASND) will report earnings on 2026-04-29, after the market close.

What are the consensus estimates for ASCENDIS PHARMA A/S - ADR (ASND) next earnings?

The consensus EPS estimate for the next earnings of ASCENDIS PHARMA A/S - ADR (ASND) is 0.3 USD and the consensus revenue estimate is 279.93M USD.

How many analysts have analysed ASCENDIS PHARMA A/S - ADR (ASND)?

The number of analysts covering ASCENDIS PHARMA A/S - ADR (ASND) is 24.